We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PTEN Gene Suggests Treatment for Melanoma

By Biotechdaily staff writers
Posted on 12 Jun 2003
Researchers have discovered that a switched-off PTEN gene allows malignant melanoma to grow and spread, suggesting that the introduction of normal PTEN into cells might represent a new therapeutic approach for the disease. More...
The findings were reported in the June 1, 2003, issue of Cancer Research.

In noncancerous cells, PTEN normally starts a chain reaction ensuring that malfunctioning and damaged cells are killed. In contrast, abnormal cancerous cells gain the ability to switch off PTEN, allowing the dysfunctional cells to survive and thrive. Accumulation of multiple changes like this in melanoma cells results in the development of a faster growing and more aggressive tumor. The researchers believe PTEN may be responsible for 30-60% of melanomas. They used chromosome transfer technology to transfer an entire chromosome 10 from healthy cells into the abnormal melanoma cells. This introduction of chromosome 10, which contains the PTEN gene, temporarily switched-off the tumor cell growth in mice and allowed cell death to resume. Eventually, however, the melanoma cells begin to grow again. Introducing the PTEN gene into melanoma cells using a harmless virus could be a new therapeutic approach for killing melanoma cells.

"These discoveries may lead to another crucial weapon in the rather small arsenal of treatments available for this dangerous disease and offer the first hope for a new melanoma treatment target in decades,” said Gavin Robertson, Ph.D., assistant professor of pharmacology, pathology, and dermatology at Penn State College of Medicine, Hershey Medical Center (Hershey, PA, USA).


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.